{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:27Z","timestamp":1788847647442,"version":"build-2803163510"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["IDUB.A46B.24.002."],"award-info":[{"award-number":["IDUB.A46B.24.002."]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["IDUB.A46B.24.002."],"award-info":[{"award-number":["IDUB.A46B.24.002."]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["IDUB.A46B.24.002."],"award-info":[{"award-number":["IDUB.A46B.24.002."]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10676-6","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:56Z","timestamp":1788845516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of heart failure pharmacotherapy on natriuresis and diuresis: A narrative review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9617-0273","authenticated-orcid":false,"given":"Berenika","family":"Jankowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-7064","authenticated-orcid":false,"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"8","key":"10676_CR1","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.7150\/ijbs.109917","volume":"21","author":"Q Luo","year":"2025","unstructured":"Luo Q, Zhang Q, Kong Y, Wang S, Wei Q (2025) Heart failure, inflammation and exercise. Int J Biol Sci 28 kwietnia 21(8):3324\u20133350","journal-title":"Int J Biol Sci 28 kwietnia"},{"key":"10676_CR2","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ehf2.14687","volume":"11","author":"O Chioncel","year":"2024","unstructured":"Chioncel O, Celutkiene J, Belohlavek J et al (2024) Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement. ESC Heart Fail 11:1861\u20131874. https:\/\/doi.org\/10.1002\/ehf2.14687","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10676_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4081\/cardio.2025.88","volume":"3","author":"SA Waqas","year":"2025","unstructured":"Waqas SA et al (2025) The impact of frailty on in-hospital outcomes in patients with HFrEF. Global Cardiol 3(4):213\u2013220","journal-title":"Global Cardiol"},{"issue":"17","key":"10676_CR4","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 18 stycznia 118(17):3272\u20133287","journal-title":"Cardiovasc Res 18 stycznia"},{"issue":"2","key":"10676_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4081\/cardio.2025.69","volume":"3","author":"W Rasool","year":"2025","unstructured":"Rasool W, Siddiqi AK, Khan LA (2025) Importance of patient-reported outcomes in cardiovascular illnesses. Global Cardiol 3(2):43\u201346","journal-title":"Global Cardiol"},{"issue":"24","key":"10676_CR6","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","volume":"21","author":"W Mullens","year":"2017","unstructured":"Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J Jun 21(24):1872\u20131882. https:\/\/doi.org\/10.1093\/eurheartj\/ehx035","journal-title":"Eur Heart J Jun"},{"key":"10676_CR7","doi-asserted-by":"publisher","unstructured":"Nijst P, Verbrugge FH, Grieten L et al (2015) The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol. Feb 3. ;65(4):378\u2013388. https:\/\/doi.org\/10.1016\/j.jacc.2014.11.025","DOI":"10.1016\/j.jacc.2014.11.025"},{"issue":"5","key":"10676_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jchf.2019.01.007","volume":"7","author":"DZ Hodson","year":"2019","unstructured":"Hodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J et al (2019) Natriuretic Response Is Highly Variable and Associated With 6-Month Survival: Insights From the ROSE-AHF Trial. JACC Heart Fail maja 7(5):383\u2013391","journal-title":"JACC Heart Fail maja"},{"issue":"20","key":"10676_CR9","doi-asserted-by":"publisher","first-page":"15472","DOI":"10.3390\/ijms242015472","volume":"24","author":"AA Manolis","year":"2023","unstructured":"Manolis AA, Manolis TA, Manolis AS (2023) Neurohumoral Activation in Heart Failure. Int J Mol Sci 23 pa\u017adziernika 24(20):15472","journal-title":"Int J Mol Sci 23 pa\u017adziernika"},{"issue":"2","key":"10676_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.33549\/physiolres.935110","volume":"73","author":"J SALAJOVA KB, MALIK","year":"2024","unstructured":"SALAJOVA KB, MALIK J (2024) Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis. Physiol Res 30 kwietnia 73(2):173\u2013188","journal-title":"Physiol Res 30 kwietnia"},{"issue":"3","key":"10676_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10741-017-9605-8","volume":"22","author":"S Rubattu","year":"2017","unstructured":"Rubattu S, Triposkiadis F (2017) Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF. Heart Fail Rev 1 maja 22(3):279\u2013288","journal-title":"Heart Fail Rev 1 maja"},{"key":"10676_CR12","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1002\/ehf2.13064","volume":"7","author":"R Zymlinski","year":"2020","unstructured":"Zymlinski R, Sierpinski R, Metra M et al (2020) Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. ESC Heart Fail 7:3536\u20133544. https:\/\/doi.org\/10.1002\/ehf2.13064","journal-title":"ESC Heart Fail"},{"key":"10676_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","volume":"345","author":"J Biegus","year":"2021","unstructured":"Biegus J, Nawrocka-Millward S, Zymlinski R et al (2021) Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Cardiol 345:54\u201360. https:\/\/doi.org\/10.1016\/j.ijcard.2021.10.149","journal-title":"Int J Cardiol"},{"issue":"4","key":"10676_CR14","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/ehf2.14920","volume":"11","author":"J Biegus","year":"2024","unstructured":"Biegus J, Zymlinski R, Ponikowski P (2024) Loop diuretics in heart failure: The objective markers to guide the therapy are needed. ESC Heart Fail 11(4):1816\u20131818","journal-title":"ESC Heart Fail"},{"key":"10676_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ejhf.2053","volume":"23","author":"J Biegus","year":"2021","unstructured":"Biegus J, Zymlinski R, Testani J et al (2021) Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail 23:729\u2013739. https:\/\/doi.org\/10.1002\/ejhf.2053","journal-title":"Eur J Heart Fail"},{"key":"10676_CR16","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41598-024-51744-x","volume":"14","author":"M Guzik","year":"2024","unstructured":"Guzik M, Iwanek G, Fudim M et al (2024) Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. Sci Rep 14:1494. https:\/\/doi.org\/10.1038\/s41598-024-51744-x","journal-title":"Sci Rep"},{"key":"10676_CR17","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/ehf2.14883","volume":"11","author":"G Iwanek","year":"2024","unstructured":"Iwanek G, Guzik M, Zymlinski R et al (2024) Spot urine sodium-to-creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure. ESC Heart Fail 11:3438\u20133442. https:\/\/doi.org\/10.1002\/ehf2.14883","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10676_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ehf2.15054","volume":"12","author":"M Guzik","year":"2025","unstructured":"Guzik M, Zymlinski R, Ponikowski P, Biegus J (2025) Urine chloride trajectory and relationship with diuretic response in acute heart failure. ESC Heart Fail Feb 12(1):133\u2013141. https:\/\/doi.org\/10.1002\/ehf2.15054","journal-title":"ESC Heart Fail Feb"},{"key":"10676_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70079","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Bozkurt B, Myhre PL et al (2025) Urinary markers in heart failure - types, timing and thresholds. European Journal of Heart Failure expert consensus document. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.70079","journal-title":"Eur J Heart Fail"},{"key":"10676_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jchf.2019.02.011","volume":"7","author":"P Martens","year":"2019","unstructured":"Martens P, Dupont M, Verbrugge FH et al (2019) Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart Failure. JACC Heart Fail 7:404\u2013414. https:\/\/doi.org\/10.1016\/j.jchf.2019.02.011","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10676_CR21","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/ehf2.15275","volume":"12","author":"M Cobo Marcos","year":"2025","unstructured":"Cobo Marcos M, de la Espriella R, Zegri-Reiriz I, Llacer P, Rubio Gracia J, Com\u00edn-Colet J, Morales-Rull JL, Diez-Villanueva P, de Juan Bagud\u00e1 J, Jim\u00e9nez-Marrero S, Ortiz Cort\u00e9s C, Restrepo-C\u00f3rdoba MA, Garc\u00eda-Pinilla JM, Barrios E, Del Prado D\u00edaz S, N\u00fa\u00f1ez J (2025) Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis. ESC Heart Fail 12(4):2460\u20132466. https:\/\/doi.org\/10.1002\/ehf2.15275 Epub 2025 Mar 28. PMID: 40152188; PMCID: PMC12287789","journal-title":"ESC Heart Fail"},{"key":"10676_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ejhf.1428","volume":"21","author":"J Biegus","year":"2019","unstructured":"Biegus J, Zymlinski R, Sokolski M et al (2019) Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail 21:624\u2013633. https:\/\/doi.org\/10.1002\/ejhf.1428","journal-title":"Eur J Heart Fail"},{"key":"10676_CR23","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1093\/eurheartj\/ehab620","volume":"42","author":"ZL Cox","year":"2021","unstructured":"Cox ZL, Rao VS, Ivey-Miranda JB et al (2021) Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J 42:4468\u20134477. https:\/\/doi.org\/10.1093\/eurheartj\/ehab620","journal-title":"Eur Heart J"},{"key":"10676_CR24","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.13372","volume":"8","author":"J Biegus","year":"2021","unstructured":"Biegus J, Zymlinski R, Fudim M et al (2021) Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Fail 8:2597\u20132602. https:\/\/doi.org\/10.1002\/ehf2.13372","journal-title":"ESC Heart Fail"},{"key":"10676_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jchf.2025.03.010","volume":"13","author":"J Biegus","year":"2025","unstructured":"Biegus J, Cotter G, Davison BA et al (2025) Diuretic De-Escalation in Response to HF Therapy: Are We Closer to Reduced Reliance on Diuretics? JACC Heart Fail 13:846\u2013854. https:\/\/doi.org\/10.1016\/j.jchf.2025.03.010","journal-title":"JACC Heart Fail"},{"key":"10676_CR26","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/ejhf.3423","volume":"26","author":"J Biegus","year":"2024","unstructured":"Biegus J, Cotter G, Metra M, Ponikowski P (2024) Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm? Eur J Heart Fail 26:2094\u20132106. https:\/\/doi.org\/10.1002\/ejhf.3423","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10676_CR27","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 21 wrze\u015bnia 42(36):3599\u20133726","journal-title":"Eur Heart J 21 wrze\u015bnia"},{"key":"10676_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","volume":"84","author":"J Biegus","year":"2024","unstructured":"Biegus J, Mebazaa A, Davison B et al (2024) Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF. J Am Coll Cardiol 84:323\u2013336. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.055","journal-title":"J Am Coll Cardiol"},{"key":"10676_CR29","doi-asserted-by":"publisher","unstructured":"Chopra V, Khan MS, Abdelhamid M et al (2025) iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Global Cardiol 3. https:\/\/doi.org\/10.4081\/cardio.2025.70","DOI":"10.4081\/cardio.2025.70"},{"key":"10676_CR30","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ehf2.14705","volume":"11","author":"KP Kresoja","year":"2024","unstructured":"Kresoja KP, Adamo M, Rommel KP et al (2024) Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair. ESC Heart Fail 11:1802\u20131807. https:\/\/doi.org\/10.1002\/ehf2.14705","journal-title":"ESC Heart Fail"},{"key":"10676_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ehf2.14863","volume":"12","author":"MG Dimond","year":"2025","unstructured":"Dimond MG, Rosner CM, Lee SB et al (2025) Guideline-directed medical therapy implementation during hospitalization for cardiogenic shock. ESC Heart Fail 12:60\u201370. https:\/\/doi.org\/10.1002\/ehf2.14863","journal-title":"ESC Heart Fail"},{"key":"10676_CR32","doi-asserted-by":"publisher","first-page":"1696793","DOI":"10.3389\/fcvm.2025.1696793","volume":"12","author":"F Zhang","year":"2025","unstructured":"Zhang F, Zhang X, Jian J, Zeng X, Zheng C, Zhang Y, Gao J (2025) Heart failure: mechanistic insights and precision therapeutic strategies. Front Cardiovasc Med 12:1696793. https:\/\/doi.org\/10.3389\/fcvm.2025.1696793","journal-title":"Front Cardiovasc Med"},{"key":"10676_CR33","doi-asserted-by":"publisher","unstructured":"Pinto FJ, Anker SD, Abraham WT et al (2025) The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide. Global Cardiol %04\/%16 3(1). https:\/\/doi.org\/10.4081\/cardio.2025.68","DOI":"10.4081\/cardio.2025.68"},{"key":"10676_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.0954-6820.1986.tb18123.x","volume":"707","author":"C Gr\u00f6nhagen-Riska","year":"1986","unstructured":"Gr\u00f6nhagen-Riska C (1986) Effects of ACE inhibition on renal regulation of salt and water. Acta Med Scand Suppl 707:95\u201399","journal-title":"Acta Med Scand Suppl"},{"key":"10676_CR35","doi-asserted-by":"crossref","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy. Circulation. 16 pa\u017adziernika. ;104(16):1985\u201391","DOI":"10.1161\/hc4101.096153"},{"issue":"19","key":"10676_CR36","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/01.cir.102.19.2325","volume":"102","author":"J Bauersachs","year":"2000","unstructured":"Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M (2000) Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 102(19):2325\u20132328. https:\/\/doi.org\/10.1161\/01.cir.102.19.2325PMID: 11067783.)","journal-title":"Circulation"},{"key":"10676_CR37","doi-asserted-by":"publisher","unstructured":"Hornych A, Safar M, Simon A, Levenson J, Bariety J, Milliez P. Effects of captopril on prostaglandin and natriuresis in patients with essential hypertension. Am J Cardiol. 1982;49(6):1524\u20131526. https:\/\/doi.org\/10.1016\/0002-9149(82)90376-9","DOI":"10.1016\/0002-9149(82)90376-9"},{"key":"10676_CR38","doi-asserted-by":"publisher","unstructured":"Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD (1987) Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol. ;4(3):330-6. https:\/\/doi.org\/10.1016\/s0168-8278(87)80542-1. PMID: 3298415.) and Gentilini","DOI":"10.1016\/s0168-8278(87)80542-1"},{"issue":"2","key":"10676_CR39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/0016-5085(93)90431-b","volume":"104","author":"P Gentilini","year":"1993","unstructured":"Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Casini Raggi V, Foschi M, Marra F, Pinzani M et al (1993) Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104(2):588\u2013594. https:\/\/doi.org\/10.1016\/0016-5085(93)90431-bPMID: 8425702.)","journal-title":"Gastroenterology"},{"issue":"6","key":"10676_CR40","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1002\/ehf2.15439","volume":"12","author":"M Massin","year":"2025","unstructured":"Massin M, Baudry G, Duarte K, Monzo L, Sadoul N, Caspi O et al (2025) Determinants of diuresis\/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure. ESC Heart Fail grudnia 12(6):3976\u20133980","journal-title":"ESC Heart Fail grudnia"},{"issue":"12","key":"10676_CR41","first-page":"1277","volume":"42","author":"G Marenzi","year":"1997","unstructured":"Marenzi G, Lauri G, Assanelli E et al (1997) [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure]. Cardiologia (Rome Italy) 42(12):1277\u20131283 PMID: 9534323","journal-title":"Cardiologia (Rome Italy)"},{"key":"10676_CR42","doi-asserted-by":"publisher","unstructured":"Nowack R, Fliser D, Richter J, Horne C, Mutschler E, Ritz E (1993) Effects of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection. Clin Investig. ;71(8):622-7. https:\/\/doi.org\/10.1007\/BF00184489. PMID: 8219659","DOI":"10.1007\/BF00184489"},{"key":"10676_CR43","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 11 wrze\u015bnia. ;371(11):993\u20131004","DOI":"10.1056\/NEJMoa1409077"},{"issue":"9","key":"10676_CR44","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.cardfail.2015.07.008","volume":"21","author":"J Buggey","year":"2015","unstructured":"Buggey J, Mentz RJ, DeVore AD, Velazquez EJ (2015) Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. J Card Fail 1 wrze\u015bnia 21(9):741\u2013750","journal-title":"J Card Fail 1 wrze\u015bnia"},{"issue":"4","key":"10676_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1755-5922.12183","volume":"34","author":"Z Kobalava","year":"2016","unstructured":"Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I (2016) Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril\/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovasc Ther 34(4):191\u2013198. https:\/\/doi.org\/10.1111\/1755-5922.12183 PMID: 26990595; PMCID: PMC5108443","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"10676_CR46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10741-024-10471-1","volume":"30","author":"P Rajzer","year":"2025","unstructured":"Rajzer P, Biegus J (2025) Sacubitril\/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations). Heart Fail Rev Mar 30(2):387\u2013405. https:\/\/doi.org\/10.1007\/s10741-024-10471-1","journal-title":"Heart Fail Rev Mar"},{"issue":"7","key":"10676_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ejhf.3265","volume":"26","author":"A Mebazaa","year":"2024","unstructured":"Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, Hayrapetyan H, Sisakian H, Ter-Grigoryan VR, Takagi K, Novosadova M, Ponikowski P, Cotter G (2024) Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: The NATRIUM-HF study. Eur J Heart Fail 26(7):1507\u20131517. https:\/\/doi.org\/10.1002\/ejhf.3265 Epub 2024 May 9. PMID: 38721803","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10676_CR48","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s00380-023-02253-w","volume":"38","author":"N Setoguchi","year":"2023","unstructured":"Setoguchi N, Horiuchi Y, Kawakami T, Nakase M, Watanabe Y, Ishizawa T, Sekiguchi M, Nakajima M, Nonaka H, Asami M, Yahagi K, Komiyama K, Yuzawa H, Tanaka J, Aoki J, Tanabe K (2023) Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure. Heart Vessels 38(8):1042\u20131048. https:\/\/doi.org\/10.1007\/s00380-023-02253-w Epub 2023 Mar 1. PMID: 36854753","journal-title":"Heart Vessels"},{"issue":"1","key":"10676_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"TD Wang","year":"2017","unstructured":"Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B et al (2017) Effects of Sacubitril\/Valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension 69(1):32\u201341. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08484","journal-title":"Hypertension"},{"issue":"9","key":"10676_CR50","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler J, Anstrom KJ, Felker GM et al (2017) Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol 2(9):950\u2013958. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10676_CR51","doi-asserted-by":"publisher","first-page":"21A","DOI":"10.1016\/0002-9149(93)90241-4","volume":"71","author":"AA van Vliet","year":"1993","unstructured":"van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW (1993) Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 21 stycznia 71(3):21A\u201328A","journal-title":"Am J Cardiol 21 stycznia"},{"issue":"6","key":"10676_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00392-015-0945-x","volume":"105","author":"JP Ferreira","year":"2016","unstructured":"Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, K\u00e9nizou D, Butler J, Zannad F, Rossignol P (2016) Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol 105(6):489\u2013507 Epub 2015 Nov 28. PMID: 26615605","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10676_CR53","first-page":"441","volume":"11","author":"J Hensen","year":"1991","unstructured":"Hensen J, Abraham WT, D\u00fcrr JA, Schrier RW (1991) Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 11(6):441\u2013446","journal-title":"Am J Nephrol"},{"key":"10676_CR54","doi-asserted-by":"publisher","unstructured":"Dawood MH, Khan MS, Rashid AM, Haverkamp W (2025) Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review. Global Cardiol %12\/%31 3(4). https:\/\/doi.org\/10.4081\/cardio.2025.91","DOI":"10.4081\/cardio.2025.91"},{"issue":"9169","key":"10676_CR55","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure (1999) Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 12 czerwca 353(9169):2001\u20132007","journal-title":"Lancet 12 czerwca"},{"issue":"9146","key":"10676_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"The Cardiac Insufficiency Bisoprolol","year":"1999","unstructured":"The Cardiac Insufficiency Bisoprolol (1999) Study II (CIBIS-II): a randomised trial. Lancet 2 stycznia 353(9146):9\u201313","journal-title":"Lancet 2 stycznia"},{"key":"10676_CR57","doi-asserted-by":"crossref","unstructured":"Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al (2001) Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med. 31 maja. ;344(22):1651\u20138","DOI":"10.1056\/NEJM200105313442201"},{"issue":"5","key":"10676_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1054\/S1071-9164(03)00133-7","volume":"9","author":"MJ Domanski","year":"2003","unstructured":"Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D et al (2003) A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail pa\u017adziernik 9(5):354\u2013363","journal-title":"J Card Fail pa\u017adziernik"},{"key":"10676_CR59","doi-asserted-by":"publisher","unstructured":"Epstein SE, Braunwald E (1966) Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. ;275(21):1175-83 concl. https:\/\/doi.org\/10.1056\/NEJM196611242752108. PMID: 5332309","DOI":"10.1056\/NEJM196611242752108"},{"issue":"2","key":"10676_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1523-1755.2005.00447.x","volume":"68","author":"G Wuerzner","year":"2005","unstructured":"Wuerzner G, Chiolero A, Maillard M, Nussberger J, Burnier M (2005) Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men. Kidney Int 68(2):688\u2013694. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00447.xPMID: 16014046.)","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10676_CR61","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1007\/BF00207623","volume":"70","author":"AG Dupont","year":"1992","unstructured":"Dupont AG (1992) Carvedilol and the kidney. Clin Investig 70(Suppl 1):S127\u2013S131. https:\/\/doi.org\/10.1007\/BF00207623PMID: 1350479.)","journal-title":"Clin Investig"},{"issue":"11","key":"10676_CR62","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","volume":"70","author":"GL Bakris","year":"2006","unstructured":"Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70(11):1905\u20131913. https:\/\/doi.org\/10.1038\/sj.ki.5001835Epub 2006 Oct 4. PMID: 17021610.)","journal-title":"Kidney Int"},{"issue":"1","key":"10676_CR63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/01.CIR.100.1.82","volume":"100","author":"GF DiBona","year":"1999","unstructured":"DiBona GF, Sawin LL (1999) Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. Circulation 6 lipca 100(1):82\u201386","journal-title":"Circulation 6 lipca"},{"issue":"12","key":"10676_CR64","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/jcdd12120484","volume":"12","author":"M Wilk","year":"2025","unstructured":"Wilk M, Tymk\u00f3w R (2025) Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022\u20132025. J Cardiovasc Dev Dis grudnia 12(12):484","journal-title":"J Cardiovasc Dev Dis grudnia"},{"issue":"3","key":"10676_CR65","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/ehf2.15184","volume":"12","author":"AP Ambrosy","year":"2025","unstructured":"Ambrosy AP, Sauer AJ, Patel S, Windsor SL, Borlaug BA, Husain M et al (2025) Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF. ESC Heart Fail 12(3):1676\u20131681","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10676_CR66","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/ehf2.14347","volume":"10","author":"JS Clemmer","year":"2023","unstructured":"Clemmer JS, Ward TJ, Lirette ST (2023) Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction. ESC Heart Fail 10(3):2010\u20132018","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10676_CR67","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1002\/ehf2.14993","volume":"11","author":"P Savage","year":"2024","unstructured":"Savage P, Watson C, Coburn J, Cox B, Shahmohammadi M, Grieve D et al (2024) Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis. ESC Heart Fail grudnia 11(6):3636\u20133648","journal-title":"ESC Heart Fail grudnia"},{"key":"10676_CR68","doi-asserted-by":"publisher","unstructured":"Usman MS, Hamid A, Qazi SU et al (2024) The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis. Global Cardiol %06\/%28 2(2). https:\/\/doi.org\/10.4081\/cardio.2024.35","DOI":"10.4081\/cardio.2024.35"},{"key":"10676_CR69","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.2967","volume":"25","author":"J Biegus","year":"2023","unstructured":"Biegus J, Fudim M, Salah HM, Heerspink HJL, Voors AA, Ponikowski P (2023) Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies. Eur J Heart Fail 25:1526\u20131536","journal-title":"Eur J Heart Fail"},{"key":"10676_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuaf019","author":"M Guzik","year":"2026","unstructured":"Guzik M, Zymli\u0144ski R, Biegus J (2026) Sodium-glucose cotransporter-2 inhibitors in heart failure. How durable is the decongestive effect? Eur J Heart Fail. https:\/\/doi.org\/10.1093\/ejhf\/xuaf019","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10676_CR71","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A et al (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail kwietnia 22(4):713\u2013722","journal-title":"Eur J Heart Fail kwietnia"},{"issue":"1","key":"10676_CR72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ejhf.2066","volume":"23","author":"EM Boorsma","year":"2021","unstructured":"Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AHJ, van Veldhuisen DJ et al (2021) Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail stycznia 23(1):68\u201378","journal-title":"Eur J Heart Fail stycznia"},{"issue":"9","key":"10676_CR73","doi-asserted-by":"publisher","first-page":"sfaf262","DOI":"10.1093\/ckj\/sfaf262","volume":"18","author":"S Flindt Nielsen","year":"2025","unstructured":"Flindt Nielsen S, Lundgreen Duus C, Henrik Buus N, N\u00f8rgaard Bech J, Holden Mose F (2025) Empagliflozin and fluid balance: results from the SiRENA project. Clin Kidney J wrze\u015bnia 18(9):sfaf262","journal-title":"Clin Kidney J wrze\u015bnia"},{"issue":"2","key":"10676_CR74","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1681\/ASN.0000000000000269","volume":"35","author":"VS Rao","year":"2024","unstructured":"Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Maulion C, Bellumkonda L et al (2024) Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. J Am Soc Nephrol JASN 1 lutego 35(2):189\u2013201","journal-title":"J Am Soc Nephrol JASN 1 lutego"},{"key":"10676_CR75","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ejhf.2852","volume":"25","author":"J Biegus","year":"2023","unstructured":"Biegus J, Zymlinski R, Testani J et al (2023) The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure. Eur J Heart Fail 25:1323\u20131333. https:\/\/doi.org\/10.1002\/ejhf.2852","journal-title":"Eur J Heart Fail"},{"key":"10676_CR76","doi-asserted-by":"publisher","first-page":"F374","DOI":"10.1152\/ajprenal.1985.248.3.F374","volume":"248","author":"B Kaissling","year":"1985","unstructured":"Kaissling B, Bachmann S, Kriz W (1985) Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 248:F374\u2013381. https:\/\/doi.org\/10.1152\/ajprenal.1985.248.3.F374","journal-title":"Am J Physiol"},{"key":"10676_CR77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000082314","volume":"24","author":"GH Kim","year":"2004","unstructured":"Kim GH (2004) Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 24:595\u2013605. https:\/\/doi.org\/10.1159\/000082314","journal-title":"Am J Nephrol"},{"issue":"5","key":"10676_CR78","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A (2024) SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback. Kidney360 5(5):771\u2013782. https:\/\/doi.org\/10.34067\/KID.0000000000000425. Epub 2024 Mar 25. PMID: 38523127; PMCID: PMC11146657","journal-title":"Kidney360"},{"key":"10676_CR79","doi-asserted-by":"crossref","unstructured":"Bhandari M, Pradhan A, Vishwakarma P, Singh A, Sethi R (2024) Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici. World J Cardiol. 26 pa\u017adziernika. ;16(10):550\u201363","DOI":"10.4330\/wjc.v16.i10.550"},{"issue":"1","key":"10676_CR80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"1","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J Jan 1(1):41\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehac530","journal-title":"Eur Heart J Jan"},{"issue":"2","key":"10676_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ehf2.14560","volume":"11","author":"G Cimino","year":"2024","unstructured":"Cimino G, Vaduganathan M, Lombardi CM et al (2024) Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail Apr 11(2):649\u2013661. https:\/\/doi.org\/10.1002\/ehf2.14560","journal-title":"ESC Heart Fail Apr"},{"issue":"4","key":"10676_CR82","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/ehf2.14641","volume":"11","author":"M Lembo","year":"2024","unstructured":"Lembo M, Strisciuglio T, Fonderico C et al (2024) Obesity: the perfect storm for heart failure. ESC Heart Fail Aug 11(4):1841\u20131860. https:\/\/doi.org\/10.1002\/ehf2.14641","journal-title":"ESC Heart Fail Aug"},{"issue":"7","key":"10676_CR83","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20(7):463\u2013474. https:\/\/doi.org\/10.1038\/s41569-023-00849-3 Epub 2023 Mar 28. PMID: 36977782","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"10676_CR84","doi-asserted-by":"publisher","first-page":"10822","DOI":"10.3390\/ijms221910822","volume":"22","author":"A Winiarska","year":"2021","unstructured":"Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stomp\u00f3r T (2021) Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. Int J Mol Sci 22(19):10822. https:\/\/doi.org\/10.3390\/ijms221910822 PMID: 34639160; PMCID: PMC8509708","journal-title":"Int J Mol Sci"},{"key":"10676_CR85","doi-asserted-by":"publisher","unstructured":"Maldonado May AC, Barron Martinez A, Berrio Becerra CA, Paulino Gonzalez D, Garcia Mena LH, Bolanos Prats F, Santillan Herrera S, Esquivel Pelayo M, Martinez Jimenez AD, Guzman Solorzano HP, Gopar Nieto R, Arias Mendoza MA, Garaygordobil DA, Impact of GLP-1 agonists on heart failure with preserved ejection fraction in obese patients: a meta-analysis of cardiometabolic and functional outcomes, European Heart Journal, Volume 46, Issue, Supplement_1 (2025) November ehaf784.1048. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf784.1048","DOI":"10.1093\/eurheartj\/ehaf784.1048"},{"issue":"9","key":"10676_CR86","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.eprac.2025.06.005","volume":"31","author":"I Khalil","year":"2025","unstructured":"Khalil I, Islam MR, Kamrul-Hasan ABM, Nagendra L, Promi SA, Sayed MA, Rahman MT, Sultana N, Tasmi NA, Das M, Tarannum S, Dey R, Dutta D (2025) Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression. Endocr Pract 31(9):1133\u20131142. https:\/\/doi.org\/10.1016\/j.eprac.2025.06.005 Epub 2025 Jun 18. PMID: 40553959","journal-title":"Endocr Pract"},{"issue":"1","key":"10676_CR87","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.cpcardiol.2025.103194","volume":"51","author":"G Caldeira Gaelzer","year":"2026","unstructured":"Caldeira Gaelzer G, Armani Prata A, Gustavo Rizzolli L, Mendes Afonso L, Lenci Marques G (2026) Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts. Curr Probl Cardiol 51(1):103194 Epub 2025 Oct 30. PMID: 41173128","journal-title":"Curr Probl Cardiol"},{"key":"10676_CR88","doi-asserted-by":"publisher","unstructured":"Ahmad B, Kumar Singh P, Shah RJ, Hammad Arif M, Goel A, Saeed M, Omar Saleh A, Amer SE, Mukhlis M, Ahmed Waqas S, Ahmed R (2025) Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety. Semergen. ;51(9):102628. https:\/\/doi.org\/10.1016\/j.semerg.2025.102628. Epub 2025 Nov 11. PMID: 41223488","DOI":"10.1016\/j.semerg.2025.102628"},{"key":"10676_CR89","doi-asserted-by":"publisher","unstructured":"Gonzales-Uribe A, Ruiz-Cortez R, Collantes-Silva N, Olivero L, Agarwal R, Arambulo-Castillo S, Garcia-Geng A, Lyu X, Mendoza-Quispe D, Becerra-Gonzales V, Butrous H (2025 Jul) Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis. Clin Res Cardiol 10. https:\/\/doi.org\/10.1007\/s00392-025-02710-8 Epub ahead of print. PMID: 40637782","DOI":"10.1007\/s00392-025-02710-8"},{"issue":"10","key":"10676_CR90","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41440-018-0070-0","volume":"41","author":"R Rodriguez","year":"2018","unstructured":"Rodriguez R, Moreno M, Lee AY, Godoy-Lugo JA, Nakano D, Nishiyama A, Parkes D, Awayda MS, Ortiz RM (2018) Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats. Hypertens Res 41(10):798\u2013808. https:\/\/doi.org\/10.1038\/s41440-018-0070-0Epub 2018 Jul 9. PMID: 29985448.)","journal-title":"Hypertens Res"},{"key":"10676_CR91","doi-asserted-by":"publisher","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","volume":"12","author":"S Puglisi","year":"2021","unstructured":"Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G (2021) Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Front Endocrinol (Lausanne) 12:738848. https:\/\/doi.org\/10.3389\/fendo.2021.738848 PMID: 34745006; PMCID: PMC8567993","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10676_CR92","doi-asserted-by":"publisher","unstructured":"Biegus J, Tymk\u00f3w R, Iwanek G, Zymli\u0144ski R, Guzik M, Hurkacz M, Sopy\u0142a W, Gajewski P, Ponikowski P. Adipokine profile in acute heart failure: associations with natriuretic response and prognosis. ESC Heart Fail. 2026;13(3):xvag150. https:\/\/doi.org\/10.1093\/eschf\/xvag150","DOI":"10.1093\/eschf\/xvag150"},{"key":"10676_CR93","doi-asserted-by":"publisher","first-page":"963","DOI":"10.17219\/dmp\/210102","volume":"62","author":"MM Wilk","year":"2025","unstructured":"Wilk MM, Wilk J, Florek K, Zimoch WJ (2025) Smoldering inflammation: The silent flame driving heart failure. Dent Med Probl 62:963\u2013976. https:\/\/doi.org\/10.17219\/dmp\/210102","journal-title":"Dent Med Probl"},{"issue":"1","key":"10676_CR94","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1038\/s41598-024-55724-z","volume":"14","author":"M Wajdlich","year":"2024","unstructured":"Wajdlich M, Nowicki M (2024) The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function. Sci Rep 14(1):5002. https:\/\/doi.org\/10.1038\/s41598-024-55724-z PMID: 38424466; PMCID: PMC10904847","journal-title":"Sci Rep"},{"key":"10676_CR95","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ehf2.15170","volume":"12","author":"L Lanser","year":"2025","unstructured":"Lanser L, Polzl G, Messner M et al (2025) Prevalence of iron deficiency in acute and chronic heart failure according to different clinical definitions. ESC Heart Fail 12:1606\u20131619. https:\/\/doi.org\/10.1002\/ehf2.15170","journal-title":"ESC Heart Fail"},{"key":"10676_CR96","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/ehf2.14849","volume":"11","author":"CC Cabrera","year":"2024","unstructured":"Cabrera CC, Ekstrom M, Tornvall P et al (2024) Iron deficiency in new onset heart failure: association with clinical factors and quality of life. ESC Heart Fail 11:2661\u20132671. https:\/\/doi.org\/10.1002\/ehf2.14849","journal-title":"ESC Heart Fail"},{"key":"10676_CR97","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/ehf2.14724","volume":"11","author":"S Sharma","year":"2024","unstructured":"Sharma S, Katz R, Chaves PHM et al (2024) Iron Deficiency and Incident Heart Failure in Older Community-Dwelling Individuals. ESC Heart Fail 11:1435\u20131442. https:\/\/doi.org\/10.1002\/ehf2.14724","journal-title":"ESC Heart Fail"},{"key":"10676_CR98","doi-asserted-by":"publisher","unstructured":"Akintunde AA, Orugun ST (2024) The association of iron deficiency with right ventricular dysfunction in Africans with heart failure. Global Cardiol 2. https:\/\/doi.org\/10.4081\/cardio.2024.53","DOI":"10.4081\/cardio.2024.53"},{"key":"10676_CR99","doi-asserted-by":"publisher","unstructured":"Aland SC, Gertler C, Br\u00e4unig HL et al (2024) Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure. Global Cardiol 2. https:\/\/doi.org\/10.4081\/cardio.2024.39","DOI":"10.4081\/cardio.2024.39"},{"key":"10676_CR100","doi-asserted-by":"publisher","unstructured":"Khan LA, Javaid SS, Butler J (2025) Iron supplementation in heart failure and iron deficiency: does it help? Global Cardiol 3. https:\/\/doi.org\/10.4081\/cardio.2025.82","DOI":"10.4081\/cardio.2025.82"},{"key":"10676_CR101","doi-asserted-by":"publisher","unstructured":"Sedlar Kobe N, Omersa D, Lainscak M, Farkas J (2024) Depression, health-related quality of life and life satisfaction in patients with heart failure. Global Cardiol %11\/%05 2(3). https:\/\/doi.org\/10.4081\/cardio.2024.47","DOI":"10.4081\/cardio.2024.47"},{"issue":"25","key":"10676_CR102","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436\u20132448. https:\/\/doi.org\/10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"issue":"11","key":"10676_CR103","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657\u2013668. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"issue":"10266","key":"10676_CR104","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"issue":"11","key":"10676_CR105","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Butler J, Ambrosy AP, Anker SD, Lam CSP, Ponikowski P et al (2023) Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 389(11):975\u2013986. https:\/\/doi.org\/10.1056\/NEJMoa2304968","journal-title":"N Engl J Med"},{"key":"10676_CR106","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised. trial Lancet 400:1938\u20131952","journal-title":"trial Lancet"},{"issue":"4","key":"10676_CR107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/FJC.0000000000000048","volume":"63","author":"C Liu","year":"2014","unstructured":"Liu C, Liu K (2014) Cardiac Outcome Prevention Effectiveness of Glucocorticoids in Acute Decompensated Heart Failure: COPE-ADHF Study. J Cardiovasc Pharmacol 63(4):333\u2013338. https:\/\/doi.org\/10.1097\/FJC.0000000000000048","journal-title":"J Cardiovasc Pharmacol"},{"key":"10676_CR108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.fjc.0000245242.57088.5b","volume":"48","author":"C Liu","year":"2006","unstructured":"Liu C, Chen H, Zhou C et al (2006) Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol 48:173\u2013176. https:\/\/doi.org\/10.1097\/01.fjc.0000245242.57088.5b","journal-title":"J Cardiovasc Pharmacol"},{"key":"10676_CR109","doi-asserted-by":"publisher","first-page":"A114","DOI":"10.1136\/heartjnl-2026-BCS.127","volume":"112","author":"M Gill","year":"2026","unstructured":"Gill M, Ardiyanto D, Ilahi HB et al (2026) 211 The diuretic effect of steroids in patients with heart failure: a rapid review, narrative synthesis and meta-analysis. Heart 112:A114\u2013A115. https:\/\/doi.org\/10.1136\/heartjnl-2026-BCS.127","journal-title":"Heart"},{"issue":"11","key":"10676_CR110","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0828-282X(07)70840-1","volume":"23","author":"C Liu","year":"2007","unstructured":"Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K (2007) Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol 23(11):865\u2013868. https:\/\/doi.org\/10.1016\/S0828-282X(07)70840-1","journal-title":"Can J Cardiol"},{"key":"10676_CR111","doi-asserted-by":"publisher","unstructured":"Zhang H, Liu C, Ji Z, Liu G, Zhao Q, Ao YG, Wang L, Deng B, Zhen Y, Tian L, Ji L, Liu K (2008) Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. ;49(5):587\u2009\u2013\u200995. https:\/\/doi.org\/10.1536\/ihj.49.587. PMID: 18971570","DOI":"10.1536\/ihj.49.587"},{"issue":"2","key":"10676_CR112","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.cardfail.2024.09.002","volume":"31","author":"J Biegus","year":"2025","unstructured":"Biegus J, Cotter G, Davison BA, Freund Y, Voors AA, Edwards C et al (2025) The effects of burst steroid therapy on short-term decongestion in acute heart failure patients with pro-inflammatory activation: a post hoc analysis of the CORTAHF randomized, open-label, pilot trial. J Card Fail 31(2):354\u2013366. https:\/\/doi.org\/10.1016\/j.cardfail.2024.09.002","journal-title":"J Card Fail"},{"key":"10676_CR113","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/ehf2.14930","volume":"11","author":"G Cotter","year":"2024","unstructured":"Cotter G, Davison B, Freund Y et al (2024) Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study. ESC Heart Fail 11:2672\u20132680. https:\/\/doi.org\/10.1002\/ehf2.14930","journal-title":"ESC Heart Fail"},{"key":"10676_CR114","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/ehf2.15235","volume":"12","author":"M Pagnesi","year":"2025","unstructured":"Pagnesi M, Cotter G, Davison BA et al (2025) Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial. ESC Heart Fail 12:1620\u20131629. https:\/\/doi.org\/10.1002\/ehf2.15235","journal-title":"ESC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10676-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10676-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:58Z","timestamp":1788845518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10676-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10676"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10676-6","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan Biegus has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures and from Alleviant Medical, Reprieve Cardiovascular, Servier, and WhiteSwell for participation in clinical trial advisory boards.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"104"}}